title: Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.
abstract: The aim of the study was to provide evidence-based recommendations for the management of early (uncomplicated) Parkinson's disease (PD), based on a review of the literature. Uncomplicated PD refers to patients suffering from the classical motor syndrome of PD only, without treatment-induced motor complications and without neuropsychiatric or autonomic problems. MEDLINE, Cochrane Library and International Network of Agencies for Health Technology Assessment (INAHTA) database literature searches were conducted. National guidelines were requested from all European Federation of Neurological Societies (EFNS) societies. Non-European guidelines were searched for using MEDLINE. Part I of the guidelines deals with prevention of disease progression, symptomatic treatment of motor features (parkinsonism), and prevention of motor and neuropsychiatric complications of therapy. For each topic, a list of therapeutic interventions is provided, including classification of evidence. Following this, recommendations for management are given, alongside ratings of efficacy. Classifications of evidence and ratings of efficacy are made according to EFNS guidance. In cases where there is insufficient scientific evidence, a consensus statement (good practice point) is made.
authors.affiliation: Department of Neurology, Radboud University Medical Centre, Nijmegen, The Netherlands. m.horstink@neuro.umcn.nl
authors.forename: M
authors.initials: M
authors.lastname: Horstink
authors.forename: E
authors.initials: E
authors.lastname: Tolosa
authors.forename: U
authors.initials: U
authors.lastname: Bonuccelli
authors.forename: G
authors.initials: G
authors.lastname: Deuschl
authors.forename: A
authors.initials: A
authors.lastname: Friedman
authors.forename: P
authors.initials: P
authors.lastname: Kanovsky
authors.forename: J P
authors.initials: JP
authors.lastname: Larsen
authors.forename: A
authors.initials: A
authors.lastname: Lees
authors.forename: W
authors.initials: W
authors.lastname: Oertel
authors.forename: W
authors.initials: W
authors.lastname: Poewe
authors.forename: O
authors.initials: O
authors.lastname: Rascol
authors.forename: C
authors.initials: C
authors.lastname: Sampaio
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use; D018450:Disease Progression; D019317:Evidence-Based Medicine; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use; D009788:Occupational Therapy; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D020734:Parkinsonian Disorders / Q000188:drug therapy; D026741:Physical Therapy Modalities; D013070:Speech Therapy
chemical_list: D000978:Antiparkinson Agents; D018696:Neuroprotective Agents